more frequent side effects
attempted suicide
suicidal ideation
depressed mood
depression
dysphoria
major depressive disorder
mood changes
comprehensive list of adverse effects
most side effects
first weeks of therapy
common side effects
least moderate severity
depression
headache
insomnia
transaminases
rash
drug
side effects
patients
increased alt
grade
grade
grade
grade
ast
grade
grade
grade
grade
total bilirubin
grade
grade
grade
incidence of hepatic enzyme elevation
patients
hepatitis b
c virus
uninfected patients
increased alt
ast
transaminasescommon
increased total bilirubinfrequency
hepatotoxicity
cholecystitis
cholelithiasis
drug-induced acute allergic hepatitis
rashfrequency
lipodystrophypostmarketing reports
severe skin
hypersensitivity reactions
including drug reaction with eosinophilia
systemic symptoms
dress
phase trials
patients
drug
least grade
therapy-related rashes
rashes
grade
weeks of therapy
total cholesterol
fasted low-density lipoprotein
ldl
cholesterol
triglycerides
appetitefrequency
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
total cholesterol
grade
grade
grade
ldl cholesterol
grade
grade
grade
triglycerides
grade
grade
insomniacommon
depression
depressed mood
depressive disorders
depressed mood
depression
dysphoria
major depression
altered mood
negative thoughts
suicide attempt
suicidal ideation
abnormal dreams
disordersfrequency
anxiety
psychiatric disorders
common side effects
treatment discontinuation
phase
clinical trials
patients
drug
psychiatric disorders
phase trials through weeks
depressive disorders
causality
severity
patients
headache
dizzinesscommon
somnolence
nausea
pancreatic amylasecommon
abdominal pain
vomiting
abdominal discomfort
lipase
dry mouthfrequency
diarrhea
postmarketing reports
severe skin
hypersensitivity reactions
including dress
increased creatininefrequency
membranous glomerulonephritis
mesangioproliferative glomerulonephritis
nephrolithiasispostmarketing reports
nephrotic syndrome
grade
creatinine
patients
phase trials
increase in serum creatinine
weeks of therapy
increase
first weeks of therapy
mean change of mg/dl
range
mg/dl
weeks of therapy
subjects with mild
moderate baseline
renal dysfunction
serum creatinine increase
subjects with normal renal function
changes
subject discontinued therapy
increases in serum creatinine
fatigue
decreased white blood cell count
hemoglobin
platelet count
immune reconstitution/reactivation syndromefrequency
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
pooled phase trials
week
overall mean change from baseline in basal cortisol
nmol/l
mcg/dl
rilpivirine
active ingredient
edurant
group
nmol/l
mcg/dl
efavirenz group
week
mean change from baseline in acth-stimulated cortisol levels
rilpivirine group
nmol/l
efavirenz group
nmol/l
mean values
acth-stimulated cortisol values at week
normal range
rilpivirine group
patients with normal mcg acth stimulation test at baseline
abnormal mcg acth stimulation test
peak cortisol level
mcg/dl
trial
patients in the efavirenz group
abnormal mcg acth stimulation test at week
rilpivirine patients
efavirenz patients
clinical significance of abnormal mcg acth stimulation tests
higher rate in the rilpivirine group
serious side effects
deaths
treatment discontinuations
adrenal insufficiency
frequency
decreased basal cortisol
adrenocorticotropic hormone
acth
stimulated cortisol levels
adrenal insufficiency
abnormal mcg acth stimulation test
stomach fullness
changes in behavior
bloody urine
discouragement
feeling
stomach pain
indigestion
irritability
lack of appetite
loss of interest
pleasure
recurrent fever
severe nausea
vomiting
swelling of the face
feet
lower legs
thoughts
killing oneself
tiredness
trouble concentrating
trouble sleeping
yellow eyes
skin
stomach discomfort
abnormal dreams
decreased appetite
diarrhea
dizziness
fear or nervousness
headache
nausea
rash
sleepiness
unusual drowsiness
unusual tiredness
weakness
vomiting
decreased amount of fat
legs
arms
face
increased amount of fat in the upper back
neck
chest
stomach area